Zeng Y, Tao G, Zeng Y, He J, Cao H, Zhang L
Front Oncol. 2024; 14:1431636.
PMID: 39534093
PMC: 11555291.
DOI: 10.3389/fonc.2024.1431636.
Luan J, Zhang D, Liu B, Yang A, Lv K, Hu P
J Transl Med. 2024; 22(1):107.
PMID: 38279111
PMC: 10821572.
DOI: 10.1186/s12967-023-04823-y.
Chen X, Qin Z, Zhu X, Wang L, Li C, Wang H
Sci Rep. 2023; 13(1):21816.
PMID: 38071230
PMC: 10710514.
DOI: 10.1038/s41598-023-49167-1.
Liu W, Qu C, Wang X
Oncol Res. 2023; 31(4):543-567.
PMID: 37415739
PMC: 10319599.
DOI: 10.32604/or.2023.029563.
Zhang L, Liu H, Long Y, Zhang Y
Open Med (Wars). 2023; 18(1):20230649.
PMID: 37333453
PMC: 10276612.
DOI: 10.1515/med-2023-0649.
Correlation between chromatin epigenetic-related lncRNA signature (CELncSig) and prognosis, immune microenvironment, and immunotherapy in non-small cell lung cancer.
Xiong Z, Han Z, Pan W, Zhu X, Liu C
PLoS One. 2023; 18(5):e0286122.
PMID: 37224123
PMC: 10208461.
DOI: 10.1371/journal.pone.0286122.
Comprehensive prediction of immune microenvironment and hot and cold tumor differentiation in cutaneous melanoma based on necroptosis-related lncRNA.
Zhang M, Yang L, Wang Y, Zuo Y, Chen D, Guo X
Sci Rep. 2023; 13(1):7299.
PMID: 37147395
PMC: 10163022.
DOI: 10.1038/s41598-023-34238-0.
Emerging RNA-Based Therapeutic and Diagnostic Options: Recent Advances and Future Challenges in Genitourinary Cancers.
Tortora F, La Civita E, Trivedi P, Febbraio F, Terracciano D, Cimmino A
Int J Mol Sci. 2023; 24(5).
PMID: 36902032
PMC: 10003365.
DOI: 10.3390/ijms24054601.
An immune infiltration-related long non-coding RNAs signature predicts prognosis for hepatocellular carcinoma.
Li G, Xu S, Yang S, Wu C, Zhang L, Wang H
Front Genet. 2022; 13:1029576.
PMID: 36568382
PMC: 9773198.
DOI: 10.3389/fgene.2022.1029576.
Surveying lncRNA-lncRNA cooperations reveals dominant effect on tumor immunity cross cancers.
Shao T, Xie Y, Shi J, Yang C, Zou H, Li Y
Commun Biol. 2022; 5(1):1324.
PMID: 36463330
PMC: 9719535.
DOI: 10.1038/s42003-022-04249-0.
Identification and Application of a Novel Immune-Related lncRNA Signature on the Prognosis and Immunotherapy for Lung Adenocarcinoma.
Zeng Z, Liang Y, Shi J, Xiao L, Tang L, Guo Y
Diagnostics (Basel). 2022; 12(11).
PMID: 36428951
PMC: 9689875.
DOI: 10.3390/diagnostics12112891.
Development of a novel immune-related lncRNA prognostic signature for patients with hepatocellular carcinoma.
Li R, Jin C, Zhao W, Liang R, Xiong H
BMC Gastroenterol. 2022; 22(1):450.
PMID: 36344926
PMC: 9639314.
DOI: 10.1186/s12876-022-02540-2.
Identification and validation of an immune-related lncRNAs signature to predict the overall survival of ovarian cancer.
Li H, Liu Z, Chen Y, Zhang X, Wu N, Wang J
Front Oncol. 2022; 12:999654.
PMID: 36313727
PMC: 9596922.
DOI: 10.3389/fonc.2022.999654.
Identification of mA-related long non-coding RNAs for predicting prognosis and immune characterizations in gastric cancer.
Zhang X, Wang C, Liu Z, Si Y
Front Genet. 2022; 13:1011716.
PMID: 36226190
PMC: 9548545.
DOI: 10.3389/fgene.2022.1011716.
Comprehensive analysis of somatic mutator-derived and immune infiltrates related lncRNA signatures of genome instability reveals potential prognostic biomarkers involved in non-small cell lung cancer.
Yang C, Yang T, Liu X, He C, Guo W, Liu S
Front Genet. 2022; 13:982030.
PMID: 36226174
PMC: 9548567.
DOI: 10.3389/fgene.2022.982030.
Predicting prognosis and immunotherapy response among colorectal cancer patients based on a tumor immune microenvironment-related lncRNA signature.
Hu C, Cai D, Zhong M, Fan D, Li C, Lv M
Front Genet. 2022; 13:993714.
PMID: 36159987
PMC: 9489948.
DOI: 10.3389/fgene.2022.993714.
Comprehensive exploration of tumor immune microenvironment feature and therapeutic response in colorectal cancer based on a novel immune-related long non-coding RNA prognostic signature.
Zhou X, Aikemu B, Li S, Shao Y, Jia H, Huang L
Front Genet. 2022; 13:962575.
PMID: 36092924
PMC: 9454821.
DOI: 10.3389/fgene.2022.962575.
Characterization of the immune related lncRNAs in bladder cancer to aid immunotherapy.
Xiao Y, Dong Y, Yu T, Wang R, Gao Y, Li S
Front Immunol. 2022; 13:941189.
PMID: 36091015
PMC: 9462669.
DOI: 10.3389/fimmu.2022.941189.
Identification of an immune-related gene signature as a prognostic target and the immune microenvironment for adrenocortical carcinoma.
Xu C, Qin C, Jian J, Peng Y, Wang X, Chen X
Immun Inflamm Dis. 2022; 10(9):e680.
PMID: 36039643
PMC: 9382862.
DOI: 10.1002/iid3.680.
A novel molecular subtypes and risk model based on inflammatory response-related lncrnas for bladder cancer.
Tang F, Zhang J, Lu Z, Liao H, Hu C, Mai Y
Hereditas. 2022; 159(1):32.
PMID: 35964079
PMC: 9375404.
DOI: 10.1186/s41065-022-00245-w.